Abstract:Parkinson's disease (PD) is characterized pathologically by the selective loss of substantia nigra (SN) dopaminergic (DAergic) neurons. Recent evidence has suggested a role of LRRK2, linked to the most frequent familial PD, in regulating synaptic vesicle (SV) trafficking. However, the mechanism whereby LRRK2 mutants contribute to nigral vulnerability remains unclear. Here we show that the most common PD mutationLRRK2 G2019Simpairs SV endocytosis in ventral midbrain (MB) neurons, including DA neurons, and the slowed endocytosis can be rescued by inhibition of LRRK2 kinase activity. A similar endocytic defect, however, was not observed in LRRK2 mutant neurons from the neocortex (hereafter, cortical neurons) or the hippocampus, suggesting a brain region-specific vulnerability to the G2019S mutation. Additionally, we found MB-specific impairment of SV endocytosis in neurons carrying heterozygous deletion ofSYNJ1(PARK20), a gene that is associated with recessive Parkinsonism. CombiningSYNJ1+/−andLRRK2 G2019Sdoes not exacerbate SV endocytosis but impairs sustained exocytosis in MB neurons and alters specific motor functions of 1-year-old male mice. Interestingly, we show that LRRK2 directly phosphorylates synaptojanin1in vitro, resulting in the disruption of endophilin-synaptojanin1 interaction required for SV endocytosis. Our work suggests a merge ofLRRK2andSYNJ1pathogenic pathways in deregulating SV trafficking in MB neurons as an underlying molecular mechanism of early PD pathogenesis.SIGNIFICANCE STATEMENTUnderstanding midbrain dopaminergic (DAergic) neuron-selective vulnerability in PD is essential for the development of targeted therapeutics. We report, for the first time, a nerve terminal impairment in SV trafficking selectively in MB neurons but not cortical neurons caused by two PARK genes:LRRK2(PARK8) andSYNJ1(PARK20). We demonstrate that the enhanced kinase activity resulting from the most frequentG2019Smutation inLRRK2is the key to this impairment. We provide evidence suggesting thatLRRK2 G2019SandSYNJ1loss of function share a similar pathogenic pathway in deregulating DAergic neuron SV endocytosis and that they play additive roles in facilitating each other's pathogenic functions in PD.

Effects of LRRK2 Inhibitors on Nigrostriatal Dopaminergic Neurotransmission

LRRK2 kinase inhibition reverses G2019S mutation-dependent effects on tau pathology progression

LRRK2 activity does not dramatically alter α-synuclein pathology in primary neurons

LRRK2 kinase inhibitors reduce alpha-synuclein in human neuronal cell lines with the G2019S mutation

Enhanced Striatal Dopamine Transmission and Motor Performance with LRRK2 Overexpression in Mice is Eliminated by Familial Parkinson's Disease Mutation G2019S

Leucine-rich repeat kinase 2 (LRRK2) inhibition upregulates microtubule-associated protein 1B to ameliorate lysosomal dysfunction and parkinsonism

Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson’s disease

Short- and Long-Term Effects of LRRK2 on Axon and Dendrite Growth.

Small-molecule LRRK2 inhibitors for PD therapy: Current achievements and future perspectives

Cell-autonomous role of leucine-rich repeat kinase in the protection of dopaminergic neuron survival

R1441C and G2019S LRRK2 knockin mice have distinct striatal molecular, physiological, and behavioral alterations

Cell autonomous role of leucine-rich repeat kinase in protection of dopaminergic neuron survival

LRRK2 Kinase Activity Does Not Alter Cell-Autonomous Tau Pathology Development in Primary Neurons

Motor Impairments and Dopaminergic Defects Caused by Loss of Leucine-Rich Repeat Kinase Function in Mice

Discovery of potent LRRK2 inhibitors by ensemble virtual screening strategy and bioactivity evaluation

LRRK2 kinase activity regulates GCase level and enzymatic activity differently depending on cell type in Parkinson's disease

LRRK2 kinase activity regulates GCase level and enzymatic activity differently depending on cell type in Parkinson’s disease

Impact of Type II LRRK2 inhibitors on signaling and mitophagy

Parkinson's Disease-Associated LRRK2 Hyperactive Kinase Mutant Disrupts Synaptic Vesicle Trafficking in Ventral Midbrain Neurons

How Parkinson's Disease-Linked LRRK2 Mutations Affect Different CNS Cell Types

LRRK2 G2019S-induced mitochondrial DNA damage is LRRK2 kinase dependent and inhibition restores mtDNA integrity in Parkinson’s disease